P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting

Nucleotide metabolism in cancer cells can influence malignant behavior and intrinsic resistance to therapy. Here we describe p53-dependent control of the rate-limiting enzyme in the pyrimidine catabolic pathway, dihydropyrimidine dehydrogenase (DPYD) and its effect on pharmacokinetics of and respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Gokare, Prashanth, Finnberg, Niklas K., Abbosh, Phillip H., Dai, Jenny, Murphy, Maureen E., El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575263/
https://www.ncbi.nlm.nih.gov/pubmed/28851987
http://dx.doi.org/10.1038/s41598-017-09859-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575263/
https://www.ncbi.nlm.nih.gov/pubmed/28851987
http://dx.doi.org/10.1038/s41598-017-09859-x

Ejemplares similares